Why did Edwards raise its full-year guidance?

Management said Q3 performance was better than expected, with TAVR growth supported by renewed clinician focus on treating aortic stenosis, new ESC/EACTS guidelines recommending intervention regardless of symptoms, and expanding indications. Strong TMTT adoption also contributed. As a result, sales growth guidance moved to the high end of 9-10%, TAVR growth to 7-8%, and adjusted EPS to $2.56-$2.62.

Why is there such a large gap between GAAP and adjusted EPS?

Q3 GAAP EPS of $0.50 included $90.4 million in certain litigation expenses, a $40.0 million intangible asset impairment, and $1.7 million in amortization, partly offset by a $12.5 million contingent consideration gain. Excluding these items, adjusted EPS was $0.67. Investors should weigh the recurring nature of litigation charges when evaluating the adjusted figure, since litigation expense rose sharply from $10.8 million a year earlier.

Is the gross margin decline a concern?

Adjusted gross margin fell to 77.9% from 80.7%, which management attributed primarily to foreign exchange and described as in line with its expectations. The effect was partly offset by growth, but investors should monitor FX exposure and any pricing pressure, as management said competitive position and pricing were largely stable globally.

How is Edwards' growth mix changing?

TAVR remains the core business at about 74% of Q3 sales. TMTT is the fastest-growing segment, up 59.3% with sales of $145.2 million, driven by PASCAL, EVOQUE, and the early launch of SAPIEN M3 in Europe. Surgical grew 7.5%. Growth in TMTT and new indications are expected to diversify revenue beyond aortic valves over time.

What risks does the filing flag for the outlook?

Guidance assumes current tariffs remain in place through 2025, and any changes to existing tariffs or new tariffs could materially affect future results. The filing also refers to risks described in Edwards' 2024 Form 10-K, including litigation, competition, and regulatory matters, as well as the uncertainty of forward-looking statements.

EW 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Edwards Lifesciences (EW) reported third-quarter 2025 results on October 30, 2025, with net sales of $1.553 billion^a, up 14.7% year over year (12.6% adjusted, which excludes FX and newly acquired products).

Growth was broad-based across product groups. TAVR sales reached $1.15 billion^b, up 12.4% (10.6% constant currency), and management said demand was better than expected as clinicians prioritized treating aortic stenosis patients, aided by new ESC/EACTS guidelines that recommend intervention regardless of symptoms. TMTT (mitral and tricuspid) sales were $145.2 million, up 59.3%, driven by PASCAL and EVOQUE, while Surgical grew 7.5% to $258 million.

Profitability was mixed. GAAP EPS was $0.50^c, but adjusted EPS was $0.67, which excludes items such as an $90.4 million litigation expense, a $40.0 million intangible asset impairment, and a $12.5 million contingent consideration gain. Adjusted gross margin fell to 77.9% from 80.7%, mainly due to foreign exchange, and SG&A rose to 33.1% of sales from 31.1% as the company invested in transcatheter therapies.

Management said adjusted operating margin of 27.5% was above expectations, partly because some spending was deferred to Q4. The company ended the quarter with roughly $3 billion^d in cash, about $600 million in total debt, and a share repurchase authorization of about $2.1 billion. Management raised full-year 2025 guidance: total sales growth is now at the high end of 9-10%, TAVR underlying growth is 7-8% (up from 6-7%), and adjusted EPS is $2.56-$2.62 (up from a prior high end of $2.45-$2.55).

Q4 guidance calls for sales of $1.51-$1.59 billion and adjusted EPS of $0.58-$0.64. Guidance assumes current tariffs remain in place, and any changes could materially affect results.

02—Key points

Key Highlights

Q3 2025 net sales rose 14.7% to $1.553 billion (12.6% adjusted), with TAVR at $1.15 billion (+12.4%, +10.6% constant currency).
TMTT sales grew 59.3% to $145.2 million, led by PASCAL and EVOQUE, and the SAPIEN M3 received CE Mark and reported ENCIRCLE trial primary endpoint results.
Adjusted EPS was $0.67 versus GAAP EPS of $0.50; the gap reflects a $90.4M litigation expense, a $40.0M intangible impairment, and other non-GAAP items.
Adjusted gross margin declined to 77.9% from 80.7%, primarily due to FX, while SG&A rose to 33.1% of sales from 31.1% on transcatheter investments.
FY2025 guidance raised: sales growth at the high end of 9-10%, TAVR underlying growth 7-8% (from 6-7%), and adjusted EPS $2.56-$2.62 (from $2.45-$2.55 high end).
Q4 2025 guidance: sales of $1.51-$1.59 billion and adjusted EPS of $0.58-$0.64.
Balance sheet remains strong with about $3B in cash, roughly $600M in debt, and a buyback authorization increased to about $2.1B.

03—Questions

Frequently Asked Questions

Why did Edwards raise its full-year guidance?
Management said Q3 performance was better than expected, with TAVR growth supported by renewed clinician focus on treating aortic stenosis, new ESC/EACTS guidelines recommending intervention regardless of symptoms, and expanding indications. Strong TMTT adoption also contributed. As a result, sales growth guidance moved to the high end of 9-10%, TAVR growth to 7-8%, and adjusted EPS to $2.56-$2.62.
Why is there such a large gap between GAAP and adjusted EPS?
Q3 GAAP EPS of $0.50 included $90.4 million in certain litigation expenses, a $40.0 million intangible asset impairment, and $1.7 million in amortization, partly offset by a $12.5 million contingent consideration gain. Excluding these items, adjusted EPS was $0.67. Investors should weigh the recurring nature of litigation charges when evaluating the adjusted figure, since litigation expense rose sharply from $10.8 million a year earlier.
Is the gross margin decline a concern?
Adjusted gross margin fell to 77.9% from 80.7%, which management attributed primarily to foreign exchange and described as in line with its expectations. The effect was partly offset by growth, but investors should monitor FX exposure and any pricing pressure, as management said competitive position and pricing were largely stable globally.
How is Edwards' growth mix changing?
TAVR remains the core business at about 74% of Q3 sales. TMTT is the fastest-growing segment, up 59.3% with sales of $145.2 million, driven by PASCAL, EVOQUE, and the early launch of SAPIEN M3 in Europe. Surgical grew 7.5%. Growth in TMTT and new indications are expected to diversify revenue beyond aortic valves over time.
What risks does the filing flag for the outlook?
Guidance assumes current tariffs remain in place through 2025, and any changes to existing tariffs or new tariffs could materially affect future results. The filing also refers to risks described in Edwards' 2024 Form 10-K, including litigation, competition, and regulatory matters, as well as the uncertainty of forward-looking statements.

04—Continue

← View all 8-K filings